Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

• Status: Completed
• Trial end date: 2018-01-08

Summary

This study will be a phase I, first time in human (FiH), randomized, single-blind, placebo-controlled, SAD study in male patients with T2DM, performed at a single study center. The study will consist of 2 parts, (A and B) up to 60 male patients with T2DM aged 18 to 65 years will be included

• Phase: Phase 1

Details

• Lead Sponsor: AstraZeneca
• Collaborators: 14050; Berlin, Germany; Parexel; PAREXEL International GmbH; Spandauer Damm 130